Amyloidosis Therapeutics Market Poised for US$ 8.20 Bn Valuation by 2032 - Persistence Market Research Analysis

The global amyloidosis therapeutics market is undergoing transformative changes, fueled by technological advancements, greater disease awareness, and evolving treatment paradigms. Valued at US$ 5.17 Bn in 2025, the market is projected to reach US$ 8.20 Bn by 2032, expanding at a CAGR of 6.8% during the forecast period from 2025 to 2032. Amyloidosis, a rare and potentially life-threatening condition caused by abnormal protein accumulation, can affect vital organs including the heart, kidneys, and liver. As early diagnosis and personalized therapies become more accessible, the market is poised for consistent growth.

According to Persistence Market Research, the primary drivers of this market include the increasing global incidence of amyloidosis, improved diagnostic technologies, and the emergence of advanced therapeutics like monoclonal antibodies, RNA-based therapies, and AI-assisted diagnostics. Chemotherapy is currently the leading segment, while North America is set to dominate due to strong healthcare infrastructure, innovative research, and favorable reimbursement scenarios.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35504

✅ Key Highlights from the Report:

➤ Chemotherapy segment will hold approximately 33% of the global market share in 2025.
➤ Hospitals & clinics are projected to dominate the end-user segment with 51% share.
➤ Rising disease awareness and targeted therapies are major market growth drivers.
➤ Dexamethasone, lenalidomide, and pomalidomide are gaining rapid traction.
➤ Home care treatment is expanding in North America and Europe.
➤ North America will hold 47% of global market share in 2025.

✅Market Segmentation

The amyloidosis therapeutics market is segmented based on treatment types such as chemotherapy, immunosuppressive drugs, and targeted therapies. Among these, the chemotherapy segment is expected to dominate, largely due to its critical role in treating AL amyloidosis. This form of therapy targets the abnormal plasma cells producing the amyloidogenic light chains. Combination therapies using high-dose melphalan, stem cell transplants, and proteasome inhibitors such as bortezomib are widely employed. Immunosuppressive drugs like corticosteroids and IMiDs are showing strong growth trends, particularly as part of combination regimens.

By end-user, the market is categorized into hospitals & clinics and home care settings. Hospitals remain the primary care centers due to their infrastructure and multidisciplinary approach involving nephrologists, hematologists, and cardiologists. However, home care settings are experiencing rapid growth, particularly in high-income regions where remote monitoring and telemedicine support chronic disease management. This trend caters to patients requiring long-term care, especially those with cardiac and systemic forms of amyloidosis.

✅ Regional Insights

North America Amyloidosis Therapeutics Market Trends

North America is projected to lead the global market, accounting for approximately 47% of revenue share by 2025. The U.S., in particular, is witnessing increased demand for newer treatments like Alnylam's Amvuttra and Pfizer's tafamidis. AI-driven diagnostics such as EchoGo Amyloidosis and integrated patient care programs like the Amyloidosis Program of Calgary are enhancing treatment access and early detection.

Europe Amyloidosis Therapeutics Market Trends

Europe is experiencing solid growth, especially in countries like Germany and the U.K., where national programs and data registries help monitor and manage amyloidosis. The approval of therapies like vutrisiran and acoramidis in the EU is expanding the therapeutic arsenal. Germany is emerging as a leader within the region, backed by robust clinical surveillance and regulatory support.

Asia Pacific Amyloidosis Therapeutics Market Trends

The Asia Pacific market is gaining momentum due to improved healthcare access, regulatory reforms, and greater investment in orphan drug development. Countries such as China and Japan are rapidly adopting advanced diagnostic tools like cardiac PYP scans. Accelerated drug approvals and inclusion of amyloidosis in national rare disease lists are expected to fuel further growth in the region.

✅Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/amyloidosis-therapeutics-market.asp

✅ Market Drivers

The amyloidosis therapeutics market is primarily driven by technological advancements in early diagnosis and treatment personalization. Non-invasive imaging, blood biomarkers, and AI-assisted diagnostics are allowing earlier detection and better prognosis, especially in cardiac amyloidosis. Public-private partnerships and research grants are fostering innovation in therapy development, including gene-silencing drugs and monoclonal antibodies.

✅ Market Restraints

Despite advancements, high treatment costs and complex diagnostic procedures are major barriers. Novel therapies such as tafamidis and patisiran can cost over US$ 200,000-500,000 annually, making them inaccessible to many patients. Additionally, the lack of consistent reimbursement and uneven healthcare infrastructure in low-income regions limits market penetration. The complexity of diagnostic tests also delays treatment initiation.

✅ Market Opportunities

There is a significant opportunity in the application of artificial intelligence (AI) in amyloidosis diagnostics and care. Tools using deep-learning CNNs are being developed to automatically identify amyloid deposits from imaging data. A promising example is an AI model developed by MedUni Vienna, trained on 16,000 patient scans, which significantly enhances early cardiac amyloidosis diagnosis. The growing interest in RNA-based therapeutics and personalized medicine also opens up future growth avenues.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35504

✅ Reasons to Buy the Report:
✔ Access detailed insights into a rare but high-growth therapeutic area
✔ Understand global and regional trends shaping the amyloidosis therapeutics landscape
✔ Evaluate the competitive landscape and key player strategies
✔ Identify future investment opportunities, including AI and personalized therapies
✔ Gain a comprehensive forecast from 2025 to 2032 based on expert analysis

✅ Company Insights: Key Players in the Market

✦ Pfizer Inc.
✦ Johnson & Johnson Services, Inc. (Janssen)
✦ GSK plc
✦ Takeda Pharmaceutical Company Limited
✦ Amgen Inc.
✦ Bristol-Myers Squibb Company
✦ Novartis AG
✦ F. Hoffmann-La Roche Ltd
✦ Merck KGaA
✦ Sanofi
✦ Alnylam Pharmaceuticals, Inc.

✅ Recent Developments

✦ In March 2025, Alnylam Pharmaceuticals announced FDA approval for AMVUTTRA® (vutrisiran) to treat transthyretin amyloidosis with cardiomyopathy (ATTR-CM).
✦ In February 2025, the European Commission granted marketing authorization for acoramidis (BeyonttraTM) for the treatment of wild-type and variant transthyretin amyloidosis in adult patients.

✅ Final Thoughts

The amyloidosis therapeutics market is at a pivotal point, propelled by medical innovation and increasing global recognition of this complex condition. From AI-enhanced diagnostics to next-generation RNA and monoclonal antibody therapies, the landscape is evolving rapidly. Market leaders are investing in research and expanding their portfolios to address various subtypes, especially AL and ATTR amyloidosis.

Persistence Market Research emphasizes that early diagnosis, affordability, and personalized medicine will determine the trajectory of the market over the next decade. With North America and Europe paving the way and Asia Pacific catching up swiftly, stakeholders need to focus on sustainable innovation, pricing strategies, and collaborative healthcare frameworks to unlock the market's full potential.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.